Louisiana State Employees Retirement System Takes $664,000 Position in Omnicell, Inc. $OMCL

Louisiana State Employees Retirement System acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,900 shares of the company’s stock, valued at approximately $664,000.

Several other hedge funds also recently bought and sold shares of OMCL. Raymond James Financial Inc. purchased a new stake in shares of Omnicell in the 2nd quarter valued at approximately $26,000. Clearstead Advisors LLC lifted its stake in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after acquiring an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Omnicell during the 4th quarter valued at about $58,000. Parkside Financial Bank & Trust boosted its holdings in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares during the period. Finally, First Horizon Corp grew its position in Omnicell by 54.6% in the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after acquiring an additional 564 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on OMCL. Craig Hallum reissued a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. KeyCorp upped their target price on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Benchmark reiterated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Zacks Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 1st. Finally, UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Omnicell has an average rating of “Buy” and an average target price of $59.86.

Omnicell Stock Down 1.8%

NASDAQ OMCL traded down $0.80 on Tuesday, hitting $44.44. 34,305 shares of the stock were exchanged, compared to its average volume of 635,248. Omnicell, Inc. has a fifty-two week low of $26.84 and a fifty-two week high of $55.00. The company has a 50-day moving average price of $41.92 and a 200-day moving average price of $41.52. The company has a market cap of $2.02 billion, a PE ratio of 101.39, a PEG ratio of 1.11 and a beta of 0.96. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The firm had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. During the same quarter in the previous year, the firm posted $0.26 earnings per share. The company’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 1.31 EPS for the current fiscal year.

Insider Transactions at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.